Tscan Therapeutics Inc

NASDAQ:TCRX   3:59:51 PM EDT
2.98
+0.10 (+3.47%)
Earnings Announcements

Tscan Therapeutics Reports First Quarter 2022 Financial Results

Published: 05/09/2022 13:46 GMT
Tscan Therapeutics Inc (TCRX) - Tscan Therapeutics Reports First Quarter 2022 Financial Results and Upcoming Anticipated Milestones.
Q1 Revenue $3.0 Million.
Ended Q1 With Cash and Cash Equivalents of $140.8 Million, Funding Operations Into 2024.
Qtrly Loss per Share $0.67.
Q1 Earnings per Share View $-0.73 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $3 Million
Adjusted EPS is expected to be -$0.74

Next Quarter Revenue Guidance is expected to be $3.66 Million
Next Quarter EPS Guidance is expected to be -$0.74

More details on our Analysts Page.